Micafungin (FK463)

01/01/2019 - "As a conclusion, high dose (10 mg/kg/day) micafungin is a safe and effective treatment choice both in the treatment of neonatal culture proven or probable invasive candida infections that were caused by refractory Candida strains, and in the case of nephrotoxicity and hepatotoxicity."
12/01/2015 - "Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits."
02/01/2015 - "The aim of this analysis was to identify therapeutic micafungin regimens for children that produce the same micafungin exposures known to be effective for the prevention and treatment of Candida infections in adults. "
04/01/2009 - "Efficacy of micafungin in treating four premature infants with candidiasis."
10/01/2006 - "Micafungin has demonstrated efficacy as antifungal prophylaxis in hematopoietic stem cell transplant recipients and in the treatment of esophageal candidiasis. "

05/01/2016 - "This is the first report to describe that micafungin is effective for P. formosus cutaneous infection in extremely premature infants."
04/07/2021 - "Previous studies have demonstrated the effectiveness of Micafungin against infections of enterovirus 71 (EV71) and chikungunya virus (CHIKV). "
05/01/2009 - "A repeated dose, open-label pharmacokinetic, and safety trial of intravenous micafungin in 12 preterm neonates >48 hours of life with suspected systemic infections. "
04/01/2003 - "However, the results of this study warrant further investigations of micafungin as a therapeutic agent for infections caused by dimorphic fungi."
12/01/2023 - "Current standard clinical micafungin dosing regimens of 1 and 2 mg/kg/day were appropriate for the prevention and treatment of Candida glabrata infection in pediatric patients undergoing HSCT, respectively. "

11/01/2006 - "This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA). "
04/01/2003 - "We tested the efficacy of micafungin (FK) alone or in combination with other antifungals against systemic murine aspergillosis. "
04/01/2003 - "Efficacy of micafungin alone or in combination against systemic murine aspergillosis."
12/01/2017 - "Few studies have assessed the efficacy and safety of micafungin in patients with proven or probable invasive aspergillosis (IA). "
12/01/2017 - "Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study."

03/31/2009 - "Micafungin is safe and effective in the treatment of children and adults with invasive candidiasis. "
02/01/2014 - "Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species."
10/05/2021 - "During the XXX (INTENSE) study into the preemptive use of micafungin to prevent invasive candidiasis (IC) after abdominal surgery, the serum burden of BDG was determined to aid diagnosis of IC. "
01/01/2021 - "High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study."
03/31/2009 - "Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates."

06/01/2004 - "Micafungin is quite useful in the treatment of deep mycoses. "
11/01/2016 - "Micafungin provides antifungal activity against Candida and Aspergillus species, and previous studies have demonstrated its efficacy when used as a prophylactic agent for fungal infection in neutropenic patients. "
11/01/2018 - "This multicentre, open-label, randomized trial compared the pharmacokinetics of 300 mg of micafungin given twice weekly with 100 mg once daily as antifungal prophylaxis in adult haematology patients at risk of developing invasive fungal disease. "
12/01/2014 - "Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany."
01/01/2006 - "All patients admitted to intensive care units (ICUs) of 3 hospitals in Chiba prefecture between June 2003 and March 2005, who were treated with micafungin because of known or suspected fungal infection, were included in the study. "